Nifty Healthcare stocks
The Nifty Healthcare has 20 member companies. The table lists each one with its price, size, valuation, growth and debt.
Close on 19 Nov 2026 · 20 member stocks (list as of 20 Nov 2026)
- 1M
- +11.5%
- 3M
- +5.3%
- 6M
- +9%
- YTD
- +18.4%
- 1Y
- +16.4%
- 3Y
- +72.6%
Price returns: index level only, dividends not included.
Today in the Nifty Healthcare
Prices at 03:29 pm IST, 20 Nov13 up, 7 down
15 of 20 trade above their 200-day average.
Near a 52-week high (1): Apollo Hospitals Enterprise
"Near" = within 1% of the highest or lowest price of the last year. Price moves only, not advice.
Top gainers
Top losers
- IPCA Laboratories−1.13%
- Sun Pharmaceutical Industries−0.79%
- Dr Reddy's Laboratories−0.76%
- Laurus Labs−0.49%
- Aurobindo Pharma−0.37%
What's new in Nifty Healthcare companies
Notable exchange filings, credit rating actions and fund raises of the last 30 days, newest first.
Strong Q2 with 13.8% sales growth and 22.5% margin, but full-year margins to stay flat as new MedTech and biotech businesses drag.
SourceGlenmark launched authorized generic Inlyta in the US targeting a $538.4m brand market.
SourceStrong H1 with 17-18% revenue growth underpins 15%+ near-term growth and heavy bed expansion.
SourceSuperb Q2 with 32% sales and 64% profit growth guides to sustained double-digit growth and major peptide-led capex.
SourceStrong 21% H1 growth with 28% margins and 15% full-year guidance plus Rs 1000 cr new capacity backs sustained double-digit profitable growth.
SourceStrong 13.8% Q2 revenue growth plus Occlutech MedTech buy offset by higher new-regime tax and Biotech losses cutting PAT.
SourceSoft Q2 with 5% sales spilling to Q3, but double-digit H2 growth, $500m new contracts and lower interest point to stronger earnings.
SourceRecord Q2 with 24% sales growth backs double-digit FY27 growth and 21%+ EBITDA margins.
Source
Nifty Healthcare in numbers
Worked out from the member companies' latest results and today's market value. Our own sums, so they can differ a little from the figures NSE publishes.
- P/E
- 42.4x
- Market value ÷ profit
- P/B
- 5.9x
- Market value ÷ book
- Dividend yield
- 0.5%
- Weighted by size
- Median ROE
- 16%
- Return on equity
- Sales growth
- +17.3%
- Median, vs a year ago
- Profit growth
- −2.7%
- Median, vs a year ago
Results for the Sep 2026 quarter
19 of 20 companies have reported. Profit grew at 9 and sales at 16 of them, against the same quarter a year earlier.
Largest members by market value
- Sun Pharmaceutical Industries19% of the total
- Divi's Laboratories12.9% of the total
- Torrent Pharmaceuticals7.5% of the total
- Laurus Labs5.5% of the total
- Apollo Hospitals Enterprise5.2% of the total
Total market value ₹ 23,73,438 Cr.. P/E covers the 20 members with a profit and a market value. Shares of the total are by full market value, not NSE's free-float weights.
Nifty Healthcare against other indices
Each line starts at 100, so you can read who gained more over the same time.
- Nifty Healthcare+16.5%
- Nifty 50−2.6%
Index levels only, dividends not included. Weekly closes beyond one year.
All 20 stocks
Changes to the Nifty Healthcare
No changes since we began tracking this list on 20 Nov 2026. NSE reviews its indices twice a year, with changes usually taking effect at the end of March and September; they will show here.